Literature DB >> 8334682

Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.

M Maeda1, T Asano, E S Kleinerman.   

Abstract

The purpose of this study was to examine the mechanisms by which liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) stimulates monocytes to produce tumor necrosis factor (TNF) and interleukin-1 (IL-1). We have previously shown that secretion of TNF protein occurred 2-4 h following incubation of monocytes with L-MTP-PE and that this stimulation of TNF production was associated with an increase in TNF mRNA. Increased intracellular interleukin-1 alpha (IL-1 alpha) and IL-1 beta were not detected until 8 h after exposure to L-MTP-PE. To determine whether TNF played a role in the stimulation of IL-1 production by L-MTP-PE, normal human monocytes were incubated with L-MTP-PE or medium in the presence or absence of anti-TNF or anti IL-1 alpha plus anti IL-1 beta. Enhanced expression of IL-1 alpha and IL-1 beta mRNA was inhibited at 4 h but not 24 h when monocytes were incubated with L-MTP-PE plus anti-TNF compared with L-MTP-PE alone. By contrast, enhanced expression of TNF mRNA was not inhibited at any time when monocytes were incubated with L-MTP-PE and anti-IL-1 alpha plus anti-IL-1 beta. These data indicate that the up-regulation of IL-1 seen in monocytes following L-MTP-PE exposure may be due in part to the production of TNF. The up-regulation of TNF, however, appears to be independent of IL-1 production.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8334682     DOI: 10.1007/bf01525436

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

1.  Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.

Authors:  M Maeda; R D Knowles; E S Kleinerman
Journal:  Cancer Commun       Date:  1991

2.  Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.

Authors:  J L Murray; E S Kleinerman; J E Cunningham; J R Tatom; K Andrejcio; J Lepe-Zuniga; L M Lamki; M G Rosenblum; H Frost; J U Gutterman
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

3.  Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer.

Authors:  P J Creaven; J W Cowens; D E Brenner; B M Dadey; T Han; R Huben; C Karakousis; H Frost; D LeSher; J Hanagan
Journal:  J Biol Response Mod       Date:  1990-10

4.  Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin.

Authors:  E S Kleinerman; R D Knowles; M B Blick; L A Zwelling
Journal:  J Leukoc Biol       Date:  1989-11       Impact factor: 4.962

5.  Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.

Authors:  I J Fidler; Z Barnes; W E Fogler; R Kirsh; P Bugelski; G Poste
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

6.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

7.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis.

Authors:  D Lovett; B Kozan; M Hadam; K Resch; D Gemsa
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

9.  Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

Authors:  I J Fidler; S Sone; W E Fogler; Z L Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

10.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors:  Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  1 in total

1.  Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat.

Authors:  K Thomas; A M Nijenhuis; B H Dontje; T Daemen; G L Scherphof
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.